Acutus Medical
Acutus Medical Q1 FY23: revenue $4.2M, up 13%; diluted EPS −$0.57
- Form
- 10-Q
- Filed
- Period
- Importance
- Notable
- Accession
- 0001628280-23-017635
- Document
- 10-Q
- Exhibit 10.1
- Material contract
- Exhibit 10.2
- Material contract
- Exhibit 10.3
- Material contract
Key figures from this report
These are the numbers Acutus Medical reported for Q1 FY23, the quarter ended Mar 31, 2023, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.
- Revenue$4.2M+13% from $3.7M in Q1 FY2210-Q income statement, on EDGAR
- Net income−$16.3MAgainst −$40.0M in Q1 FY2210-Q income statement, on EDGAR
- Diluted EPS−$0.57Against −$1.42 in Q1 FY2210-Q income statement, on EDGAR
- Cash and cash equivalents$22.7M+85% from $12.3M in Q1 FY22Cash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
- Cash from operations−$16.5MAgainst −$27.6M in Q1 FY2210-Q cash flow statement, on EDGAR
Similar companies
Companies of similar size in SIC 3841 and related industry codes: the same peer list as the financial tables.
- Adagio Medical Holdings ADGM
- Aethlon Medical AEMD public float $6M, Sep 30, 2025
- ALR Technologies SG ALRTF
- Allurion Technologies ALUR public float $21M, Jun 30, 2025
- Autonomix Medical AMIX public float $6M, Sep 30, 2025
